China biocontroversy & diversity matters — BioCentury’s latest podcast

Plus: a setback for Amylyx in ALS and Lilly Alzheimer’s therapy in FDA spotlight

Last week’s meeting of the Select Committee on the Chinese Communist Party about the intersection of biotech and national security provided a glimmer of hope that lawmakers could be persuaded to consider taking steps to bolster the U.S. bioeconomy, BioCentury Washington Editor Steve Usdin said. Discussing his latest Editor’s Commentary on the BioCentury This Week podcast, Usdin explains why the at times cartoonish spectacle of lawmakers pushing anti-China biotech bills highlights the need for scientists and entrepreneurs to build relationships in Washington.

Editor in Chief Simone Fishburn expands on her Editor’s Commentary, which argues the future of diversity should not be bound up in the fate of DEI.

And BioCentury Executive Editor Selina Koch joined the podcast to discuss the pivotal trial setback for  Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) in amyotrophic lateral sclerosis (ALS) and what may be on FDA’s agenda as the agency schedules an advisory committee meeting for donanemab, an Alzheimer’s mAb from Eli Lilly and Co. (NYSE:LLY).

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at conferences@biocentury.com. To watch the latest BioCentury Show, which features a conversation with bioethicist Arthur Caplan visit BioCentury’s YouTube channel.